Based on the Bionik Laboratories Corp stock forecast from 0 analysts, the average analyst target price for Bionik Laboratories Corp is not available over the next 12 months. Bionik Laboratories Corp’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Bionik Laboratories Corp is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Bionik Laboratories Corp’s stock price was USD 0.00. Bionik Laboratories Corp’s stock price has changed by 0% over the past week, 0% over the past month and -100.00% over the last year.
No recent analyst target price found for Bionik Laboratories Corp
No recent average analyst rating found for Bionik Laboratories Corp
Company Overview Bionik Laboratories Corp
N/A
N/A
N/A
N/A
USD
USA
Adjusted Closing Price for Bionik Laboratories Corp (BNKL)
Loading...
Unadjusted Closing Price for Bionik Laboratories Corp (BNKL)
Loading...
Share Trading Volume for Bionik Laboratories Corp Shares
Loading...
Compare Performance of Bionik Laboratories Corp Shares
Frequently Asked Questions About Bionik Laboratories Corp (BNKL) Stock
Stock Target Advisor's fundamental analysis for Bionik Laboratories Corp's stock is Bearish.
Unfortunately we do not have enough data on BNKL's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BNKL's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BNKL's stock to indicate if its overvalued.
The last closing price of BNKL's stock was USD 0.00.
Unfortunately we do not currently have any market capitalization data for BNKL's stock.
Unfortunately we do not have enough analyst data on BNKL's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bionik Laboratories Corp's stock.
Sorry, we do not have any data on the number of employees for Bionik Laboratories Corp.
Sorry we do not have any infomation available on Bionik Laboratories Corp's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Bionik Laboratories Corp (BNKL) Stock
Stock Target Advisor's fundamental analysis for Bionik Laboratories Corp's stock is Bearish.
Unfortunately we do not have enough data on BNKL's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BNKL's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BNKL's stock to indicate if its overvalued.
The last closing price of BNKL's stock was USD 0.00.
Unfortunately we do not currently have any market capitalization data for BNKL's stock.
Unfortunately we do not have enough analyst data on BNKL's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bionik Laboratories Corp's stock.
Sorry, we do not have any data on the number of employees for Bionik Laboratories Corp.
Sorry we do not have any infomation available on Bionik Laboratories Corp's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BNKL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
